Company Profile

Harmony Biosciences Stock Price, News & Catalysts

Ticker:
HRMY
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

32.98 USD (-0.39%)

Close

Last updated: November 19, 2026

1.79B USD

Market cap

Why the stock is moving

The latest company update was “Harmony Biosciences to Participate in Upcoming Investor Conferences”. HRMY changed 0.39% and closed at $32.98 on Nov 19, 2026, indicating a relatively limited closing-price reaction to this conference / presentation update.

Company overview

Sleep and Neurologic Disorders

Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.

WAKIX Franchise

WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.

Pitolisant Lifecycle Programs

Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.

Orexin-2 Program

BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.

Future catalysts

  • Updated 18-month ARGUS data at the AES Annual Meeting in December 2026.
  • Phase 1b BP-205 data in the first quarter of 2027, followed by Phase 2 study starts by mid-2027.
  • FDA action on the pitolisant gastro-resistant formulation on April 1, 2027, with a potential launch in the first half of 2027.
  • Topline Phase 3 data for high-dose pitolisant in 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Harmony Biosciences (HRMY)?

Harmony Biosciences (HRMY) most recently closed at 32.98 USD, a -0.39% move versus the previous session.

What is the market cap of Harmony Biosciences (HRMY)?

Harmony Biosciences currently has a market capitalization of 1.79B USD on BioPharmSignal.

What does Harmony Biosciences do?

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal...

On which exchange is HRMY stock listed?

Harmony Biosciences (HRMY) is associated with NASDAQ, United States, Biopharma.

What is BP-205?

Phase 1b BP-205 data in the first quarter of 2027, followed by Phase 2 study starts by mid-2027.

Which conditions is Harmony Biosciences targeting with BP-205?

Phase 1b BP-205 data in the first quarter of 2027, followed by Phase 2 study starts by mid-2027.

How does Harmony Biosciences describe recent progress with BP-205?

Phase 1b BP-205 data in the first quarter of 2027, followed by Phase 2 study starts by mid-2027.

What is Sleep?

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases.